#$%$ already...enough of your #$%$. You don't like it, SELL it....if you're short, well keep it.
Bigs - why don't you just get out of your position if you are long? Your efforts to manipulate this stock are unprecedented in my experience on these boards. The sad part is that you do a fantastic job of that because the avg daily volume on this stock is less than 100k.
You do realize that efficacy is THE WHOLE POINT of this trial.....you definitely put a lot of effort into trying to manipulate the price on a stock with thin float.
Canaccord Genuity analyst Jason Mills was out pounding the table on Sunshine Heart Inc (NASDAQ:SSH) Thursday, reiterating a Buy rating and a $7.50 price target, which represents a potential upside of 82.5% from where the stock is currently trading.
Mills noted, "We would be buyers of SSH common, which we think could move higher once the US trial “pause” is lifted and enrollment re-accelerates. We continue to believe SSH offers investors the opportunity to participate in a nascent growth company that is commercializing potentially disruptive technology for the treatment of moderate heart failure. We remain positive on the long-term prospects for SSH's differentiated technology in the treatment of Class III heart failure; thus, we maintain our BUY rating."
Agreed. This company needs investors and would be great to flush all the short term traders out, but that is just not possible, so with this type of float, the pps will fluctuate quite a bit.
versus a disease that has a 100% mortality rate?? and by the way, the deaths are not being blamed on the C-Pulse.
Perfect question for you to ask during the conference call.
Wow, the board looks so much cleaner without his posts. I am not sure of what I think the deal is with the cancellation of the presentation and NOT putting out a press release.....strange. In my opinion, it could very well mean a buyout, but I would rather take my chances with SSH alone and see the trial through.